Glaxo SmithKline Biologicals sa | Date: 2012-05-25
The present invention provides formulations of an immunogenic composition containing a purified inactivated Dengue virus, and method for producing them.
Glaxo Smith Kline Biologicals S.A. | Date: 2011-02-06
The present invention provides an immunogenic composition comprising one or more antigens and a Toll-like receptor (TLR) agonist in an orally (e.g. sublingually) administered composition.